Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


PEER-REVIEWED ARTICLES

Americas Antibody Congress 2017

FRESH DATA. EXPERT SPEAKERS. DEEP CONTENT.

This May, researchers from pharma, academia, and biotech will descend on San Diego for two days of networking and content on the challenges to the antibody industry presented by the increased demand for antibody drugs to fight chronic illnesses.

With demand comes innovation. The only antibody event with new data and non-repetitive talks as a requirement to speak, Americas Antibody Congress 2017 will feature sessions on New Data in Antibody Discovery, New Data in Clinical and Commercial Development, and the therapeutic areas of Infectious Diseases and Oncology.

Download the brochure

Click here tot register


 

World Immunotherapy Congress USA 2017

Discover. Develop. Get to market. For Biotech, Pharma, and Their Partners.

The demand for innovation in immunotherapy can only grow, and new breakthroughs are needed if success rates are to continue. That’s why World Immunotherapy Congress is coming to the USA after an acclaimed launch in Europe. This inaugural event will bring together the brightest and best minds in pharma, biotech, government and academia to build on the development and commercialization of new immunotherapy treatments.

Co-located with the Americas Antibody Congress, Immunotherapy World Congress USA features 2 days of in-depth case studies and discussions around Cell Therapy Strategies, Pre-Clinical Development and Innovative Therapeutic Approaches presented by our partners from biopharma and academia.

Click here to register.


 

CPhI | Pre-Connect Congress 2017

CPhI’s Pre-Connect Congress is the ‘Pharma Leaders’ Destination’ – a one day Congress taking place the day before the CPhI Worldwide Exhibition and covering the latest trends and developments in Pharma across a variety of sectors.

The Pre-Connect Congress is the only event to cover the full spectrum of the Pharma value chain.

Join us in Frankfurt on 23rd October for a series of thought provoking presentations, interactive panel discussions and dedicated networking opportunities, helping you to do better business in Pharma.

7th Annual World ADC Berlin 2017

The last 12 months has seen a staggering amount of progress in ADCs.

There are now 50+ compounds in the clinic; with approval of Pfizer’s Inotuzumab Ozogamicin expected later this year. Coupled with this, there is a bulging preclinical pipeline of 92 ADCs and counting.

In 2017, 300+ of the leading ADC minds will descend on the 7th Annual World ADC Berlin meeting (20-22 February) to share experiences, data and insights on how to develop the next generation of clinically impactful ADCs. Across three streams, every element of ADC development is addressed providing you with an unrivalled forum for learning.

The 2017 World ADC Berlin program has been designed to reflect these progressive innovations developing next-generation ADCs.

The meeting will be held in the Maritim proArte Hotel Berlin,  Friedrichstraße 151,  Berlin,  10117, Germany

Antibody Drug Conjugates Summit

The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness
  • Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
  • Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:

  • Toxicology
  • Biologics
  • Molecular Biology
  • Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
  • Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
  • Oncology Drug Development; Oncology Molecules
  • Medical information
  • Bioanalytical
  • Discovery Chemistry; Research & Development; Antibody Discovery
  • Protein Engineering; Process Sciences
  • Biopharmaceutical Development; Development Analytics and New Technologies:
  • Clinical Assay; Biologics Discovery and Design

It is also designed for professionals who work for the Industry of:

  • Pharmaceuticals,
  • Biologics,
  • Medicine;
  • Clinical Research Organizations;
  • Academic Research Centers;
  • Regulatory Agencies

 

8th World ADC

Now in it’s 8th year, World ADC in San Diego , CA, shares novel science with transformative research to power the development of more therapeutically effective Antibody-drug Conjugates (ADCs).

This multi-stream, 4 day event covers every element of ADCs from early discovery to marketization. Distilling new insights and data with lessons learned, attendees will be able to craft their own ADC conference focused on your specific challenges.

As the industry’s definitive conference, this antibody drug conjugate conference provides you with an unrivaled forum for learning to propel your ADC program forward tomorrow.

Organized by Hanson Wade, the 8th World ADC in San Diego will be held at Sheraton San Diego Marina, 1380 Harbor Island Dr, San Diego, CA 92101, United States.

Antibody-drug Conjugate Summit

The Curtis & Wyss Group is pleased to invite you to the, “Antibody Drug Conjugate summit” scheduled on May 22 – 23, 2017 in Lisbon, Portugal. This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, pre-clinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving pre-clinical and clinical translation and creating strong and salable processes.

It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Lisbon!

Key Practical Learning Points of the Summit:

  • Increase benefits of ADCs – dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

12th Annual European Antibody Congress

Focusing on discovery, development and getting to market the European Antibody Congress is the perfect arena to showcase your technologies, and equipment along with regulatory, manufacturing and research services to leading pharma, biotech, academia and research institutes.

The 12th annual European Antibody Congress (November 14th-16th) will once again be held in Basel in partnership with the City of Basel in Switzerland.


 

Second International Conference on Antibody/Targeted-drug Conjugates: New Developments & Updates

The concept of using biologics and particles including monoclonal antibodies (mAbs) to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding non-specific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics and conjugation methodology, in developing effective targeted drug conjugates with acceptable safety/toxicity profiles.

The second International Conference Antibody/Targeted-drug Conjugates (ADTC) New Developments & Updates conference to be held in Leiden, The Netherlands in March 2017 will aim to examine the concept and future of targeted drug delivery systems. The scientific program will include keynote lectures, contributed papers and poster presentations emphasizing all key aspects and recent developments surrounding targeted drug delivery systems.

Conference scope and topics:

  • Novel ADC targets/ADC target discovery/target disease indications (including non-cancer targets)
  • Novel payloads/modes of action (beyond tubulin binders)
  • Biological components (antibody & antibody-like formats; molecularly defined conjugation sites)
  • Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers
  • Next generation ADCs (site-specifically conjugated, including enzymatic conjugation
  • Immunotoxins
  • Chemistry approaches: mediating high toxicity of new warheads currently in use
  • Chemical modifications of ADC structure and linkers
  • Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction
  • Other carrier/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones and their analogues, small molecules, liposomes, vitamins)
  • Manufacturing/Regulatory issues
  • Process development (robustness, scalability)
  • Clinical stage ADCs/ongoing clinical trials, clinical translation

The second International Conference Antibody/Targeted-drug Conjugates (ADTC) New Developments & Updates conference is the sister meeting to the established human antibodies series ‘Human Antibodies & Hybridomas.


Download brochure for more information and join the conversation on Twitter – #ATDC2017

PEGS | Boston 2017

PEGS Summit will return to Boston May 1-5, 2017 for another inspiring week-long event providing an exclusive platform for collaboration and discussion among a variety of academic and industry perspectives.

Network with world-class experts from pharma, academia, and government to share information, case studies, and best practices covering a vast area of biologic drug development and hear in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytical, immunogenicity, and therapeutics.

Oncology
The Oncology Stream will highlight the great strides and best practices for antibody-based therapeutics, including novel bispecific antibodies, ADCs and immunotherapy approaches that promise improved properties, greater efficacy, and clinical translation. Tools for choosing optimal constructs and combination therapy will enable a significant number of these molecules to advance to the clinic and enable precision targeting of cancer

Antibodies for Cancer Therapy
The Seventh Annual Antibodies for Cancer Therapy meeting has become a critical forum for learning the newest trends in designing antibodies against oncology targets. This meeting will review current strategies and recent developments with novel constructs and emerging targets for oncology. Leaders in the community will discuss advances and share learning experiences with the audience to facilitate knowledge sharing and improve our success rate in this important area. Much progress has been made recently, so don’t miss this chance to gain wisdom that will impact your work.

Advancing Bispecific Antibodies & Combination Therapy to the Clinic
At the Fifth Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference, leaders will share insights and review encouraging clinical data. The proliferation of novel multi-specific antibody constructs and combination therapy approaches has yielded exciting results, and this meeting will delve into solutions for improving the technology and selecting the best molecules for manufacturing and developability concerns.

Bioconjugation
The Bioconjugation Stream brings together 2 promising and exciting proteins in the category – Fusion Proteins and Antibody-Drug Conjugates – and explores their current and future prospects as therapeutics. The Fusion Protein Therapeutics conference explores the varying constructs of fusion protein molecules to deliver higher efficacy, greater specificity and longer half-lives. The Antibody-Drug Conjugates I conference underlies the industry’s greater understanding of ADC chemistry and biology, prompting creative design and engineering of next-generation linkers, payloads and antibodies; while Antibody-Drug Conjugates II conference invites scientists to share their latest clinical results and lessons learned to help advance their molecules and drive clinical success.

Fusion Protein Therapeutics
The customizable functionality of Fusion Protein Therapeutics creates advantages over antibody-based therapies by combining modular building blocks that can reach targets not accessible to antibodies. Additional advantages include lower patient dosing, reduced production costs, and improved product homogeneity. The Fusion Protein Therapeutics conference explores the varying constructs and ‘designs’ of fusion protein molecules, and will disclose how they are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life. Experts will present case studies from R&D through clinical data, and will share the results they’ve achieved.

Antibody-drug Conjugates
This is an exciting time for antibody-drug conjugate developers. With many ADCs moving into later-stage clinical trials, the industry is eagerly anticipating the results from these trials. Some of the lessons learned from earlier trials have already been applied to new generations of ADC design, helping the industry to overcome the setbacks previously experienced. The industry is now eagerly anticipating data from new pivotal trials in solid tumors, results from trials with new payloads and linkers, and outcomes from combination therapies.

Lessons learned from the two marketed ADCs and the ongoing ADC trials have not only enabled scientists to better understand the mechanisms of action of antibody-drug conjugates, but also helped invigorate a new field of ADC study aimed at overcoming the challenges of poor internalization, tumor non-specificity, off-target toxicity, lack of efficacy, low expression levels and multi-drug resistance. Today, scientists continue to innovate on next generation ADCs by improving target selection, finding new cytotoxic drugs as warheads, engineering antibodies or discovering alternative effector moieties to increase half-lives and improve target specificity, optimizing linker-payload chemistry to produce stable and homogeneous ADCs, and overcoming the challenges of multi-drug resistance.

Antibody-Drug Conjugates I: New Targets, Payloads and Chemistry
The Antibody-Drug Conjugates I: New Targets, Payloads and Chemistry conference will present scientists’ creativity in the design and optimization of next-generation bioconjugates.

Antibody-Drug Conjugates II: Advancing Toward the Clinic
During the Antibody-Drug Conjugates II: Advancing Toward the Clinic conference, scientists will present their latest clinical and preclinical data, as well as lessons learned to help drive the industry toward clinical success.


 


Skip to toolbar